sunitinib malate — United Healthcare
thyroid carcinoma
Preferred products
- Caprelsa
- Cometriq
Initial criteria
- Option 1:
- All of the following:
- Diagnosis of follicular carcinoma, oncocytic carcinoma, or papillary carcinoma
- AND unresectable locoregional recurrent disease OR persistent disease OR metastatic disease
- AND symptomatic disease OR progressive disease
- AND disease refractory to radioactive iodine treatment
- OR Option 2:
- Diagnosis of medullary thyroid carcinoma
- AND progressive disease OR symptomatic metastatic disease
- AND one of the following:
- Clinical trials or preferred systemic therapy options are not available or appropriate
- There is progression on preferred systemic therapy options (e.g., Caprelsa [vandetanib], Cometriq [cabozantinib])
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Sutent therapy
Approval duration
12 months